Ractigen Therapeutics Announces Completion of Enrollment and First Dosing in Phase II Clinical Trial of RAG-17 for SOD1-ALS
One daysingle sourceOne outlet reported this, once - no second voice in this corpus.
All 1 reports on Thu, 6 August 2026
What it is about
Zhan-Yu ZouHui-Fang ShangJing-Sheng ZengZhi-Ying WuTerms Of ServiceProgram Of The CenterDrug AdministrationNational Medical Products AdministrationZhejiang, Zhejiang, ChinaChinaManila, Manila, PhilippinesLong Wang, Anhui, ChinaCheng Li, Guangdong, ChinaSichuan, Gansu, ChinaFujian, Fujian, ChinaNantong, Jiangsu, China
Who published it, and when
How it spread - 1 original report
Thu, 6 August 2026
1 report- manilatimes.net11:56first to report
NANTONG, China, Aug. 6, 2026 /PRNewswire/ -- Ractigen Therapeutics, a clinical-stage biotechnology company pioneering next-generation RNA therapeutics, today announced the completion of patient enrollment and initial dosing across all cohorts in its Phase II clinical trial evaluating RAG-17, an investigational siRNA therapy targeting superoxide dismutase 1 (SOD1) mutations in amyotrophic lateral sclerosis (ALS).